Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma
针对无法切除的IV期黑色素瘤患者,一项II期临床试验评估了调节性T细胞清除剂denileukin diftitox的疗效
期刊:BMC Cancer
影响因子:3.4
doi:10.1186/1471-2407-11-515
Telang, Sucheta; Rasku, Mary Ann; Clem, Amy L; Carter, Karen; Klarer, Alden C; Badger, Wesley R; Milam, Rebecca A; Rai, Shesh N; Pan, Jianmin; Gragg, Hana; Clem, Brian F; McMasters, Kelly M; Miller, Donald M; Chesney, Jason